Aurobindo Pharma
AUROPHARMA · Pharma > Pharmaceuticals & Drugs · Chairman: K Ragunathan · MD: N Govindarajan · Listing date: June 14, 1995 · Employees: 19364 · Hyderabad · http://www.aurobindo.com

Stock Price vs Company Growth
1d
0.9%
1w
0.1%
1m
20.7%
3m
25.6%
6m
56.5%
1y
122.5%
5y
5.8%
10y
22.2%
all
17.9%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

1,034 0.9%
813
1,059
Company Overview

Sales
26,950 Cr
Growth: 6.9%
Profit after Tax
2,325 Cr
Growth: 17.6%
Large Cap
60,563 Cr
P/E: 26.1x
Industry P/E: 31.7x
Fundamentals

Sales (Cr) ₹ 26,950
Growth 6.9%
EBITDA 16.6%
P/S 2.2x
Dividend 1.5%
P/E 26.1x
Book Value ₹ 481
PEG Ratio 3.8x
ROE 8.6%
P/B 2.2x
Shareholding Pattern

Institutions
Life Insurance Corporation Of India
3.46 %
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund
3.4 %
Qualified Institutional Buyer
1.95 %
Nippon Life India Trustee Ltd-A/C Nippon India Pharma Fund
1.32 %
Bnp Paribas Arbitrage
1.22 %
Promoters
Rpr Sons Advisors Private Limited, Mrs.P.Suneela Rani (Jointly Holding)
33.51 %
K Nityananda Reddy
4.33 %
Kirthi Reddy Kambam
3.49 %
Venkata Ramprasad Reddy Penaka
3.07 %
Axis Clinicals Limited, Trident Chemphar Limited, Rpr Sons Advisors Pvt.Ltd. (Jointly Holding)
2.85 %
Others
Increase    Decrease    No change
Company Profile Detailed

Aurobindo Pharma continues to be one of the world’s fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration.
Investors (185)
Followers (73)